ReviewExperimental & molecular medicine2025
MAP4K signaling pathways in cancer: roles, mechanisms and therapeutic opportunities.
Review in Experimental & molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Cancer drug response and resistance: molecular mechanisms and combating strategies.Signal transduction and targeted therapy · 2026Review
- Central toxic effects of an antitumoral bufadienolide: In silico targets and in vivo findings.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Integrative omics identify NID2 as a therapeutic target linking depression and colorectal cancer in humans.iScience · 2026Article
- Phosphosite-specific co-regulation networks of MELK kinase: insights from integrative global phosphoproteomes.Journal, genetic engineering & biotechnology · 2026Article
- Combined Curcumin and Doxorubicin Induce Apoptosis via JNK-Dependent MAPK Signaling Independent of TXNDC5 in Human Osteosarcoma Cells.Nutrients · 2026Article
- The Role of CRISPR and Its Therapeutic Applications in Glioblastoma.International journal of molecular sciences · 2026Review
- RAP-2-independent roles formicroPublication biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The MAP4K family, consisting of seven kinases (MAP4K1-7), plays crucial roles in regulating diverse cellular processes, including proliferation, differentiation, migration and apoptosis. Recent studies have highlighted their involvement in multiple signaling pathways such as mitogen-activated protein kinase, Jun N-terminal kinase and Hippo, implicating them in conditions such as cancer, autoimmune and metabolic disorders and neurodegenerative diseases. Notably, MAP4K proteins have demonstrated significant roles in cancer development and progression, including tumor growth, metastasis and immune modulation. Here we summarize current insights into the roles of individual MAP4K members in cancer and other diseases, emphasizing their distinct and overlapping functions within key signaling networks. Furthermore, we discuss the therapeutic potential of targeting MAP4K family members for cancer treatment. These kinases represent promising targets for developing novel therapies for cancer and related diseases. Future research is essential to clarify the specific molecular mechanisms of MAP4K proteins in cancer and to explore their broader relevance in health and disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.